MXPA05008677A - Particulas quimericas de hbc estabilizadas como vacuna terapeutica para hepatitis cronica. - Google Patents
Particulas quimericas de hbc estabilizadas como vacuna terapeutica para hepatitis cronica.Info
- Publication number
- MXPA05008677A MXPA05008677A MXPA05008677A MXPA05008677A MXPA05008677A MX PA05008677 A MXPA05008677 A MX PA05008677A MX PA05008677 A MXPA05008677 A MX PA05008677A MX PA05008677 A MXPA05008677 A MX PA05008677A MX PA05008677 A MXPA05008677 A MX PA05008677A
- Authority
- MX
- Mexico
- Prior art keywords
- terminus
- chronic hepatitis
- particles
- immunogenic
- therapeutic vaccine
- Prior art date
Links
- 239000002245 particle Substances 0.000 title abstract 4
- 241000251204 Chimaeridae Species 0.000 title abstract 2
- 206010008909 Chronic Hepatitis Diseases 0.000 title 1
- 208000006454 hepatitis Diseases 0.000 title 1
- 229940021747 therapeutic vaccine Drugs 0.000 title 1
- 230000002163 immunogen Effects 0.000 abstract 3
- 229960005486 vaccine Drugs 0.000 abstract 2
- 208000000419 Chronic Hepatitis B Diseases 0.000 abstract 1
- 241000700721 Hepatitis B virus Species 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10123—Virus like particles [VLP]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se describe un metodo para tratar hepatitis B cronica, el cual comprende administrar una cantidad de celulas T que estimulan la hepatitis B de una vacuna a un paciente. La vacuna comprende una cantidad inmunogenica de quimerica, la proteina (HBc) de nucleocapsida (nucleo) del virus de la hepatitis B truncada con carboxi terminal que se disena tanto para estabilidad mejorada de particulas auto-agrupadas y la ausencia sustancial de la union del acido nucleico por aquellas particulas. La molecula de proteina quimerica puede incluir uno o mas epitopes inmunogenicos de peptido unido a uno o mas del termino N, el bucle inmunogenico o el termino C de HBc. La estabilidad mejorada de particulas auto-agrupadas se obtiene por la presencia de al menos un residuo de cisteina heterologa cerca uno o ambos del termino amino y el termino carboxi de la molecula quimerica.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/372,076 US20030198645A1 (en) | 2002-02-21 | 2003-02-21 | Stabilized HBc chimer particles as therapeutic vaccine for chronic hepatitis |
US10/677,074 US7351413B2 (en) | 2002-02-21 | 2003-10-01 | Stabilized HBc chimer particles as immunogens for chronic hepatitis |
PCT/US2004/005047 WO2004075836A2 (en) | 2003-02-21 | 2004-02-20 | STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05008677A true MXPA05008677A (es) | 2006-02-22 |
Family
ID=32930197
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05008677A MXPA05008677A (es) | 2003-02-21 | 2004-02-20 | Particulas quimericas de hbc estabilizadas como vacuna terapeutica para hepatitis cronica. |
Country Status (12)
Country | Link |
---|---|
US (1) | US7351413B2 (es) |
EP (1) | EP1601327A4 (es) |
JP (1) | JP2007525421A (es) |
KR (1) | KR100815408B1 (es) |
CN (1) | CN101080239A (es) |
AU (1) | AU2004216246B2 (es) |
BR (1) | BRPI0407632A (es) |
CA (1) | CA2516640A1 (es) |
MX (1) | MXPA05008677A (es) |
NZ (1) | NZ541702A (es) |
WO (1) | WO2004075836A2 (es) |
ZA (1) | ZA200507617B (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1218514B1 (en) * | 1999-10-08 | 2006-04-26 | Celltech Pharma Europe Limited | Designing immunogens |
ATE336502T1 (de) * | 2000-04-07 | 2006-09-15 | Univ Leeds | Hepatitis b kernprotein fusionsproteine |
ATE546156T1 (de) * | 2002-12-10 | 2012-03-15 | Sanofi Pasteur Biologics Co | Stabilisierte immunogene chimäre hbc-partikel |
PL1802746T3 (pl) * | 2004-10-27 | 2011-10-31 | Crucell Switzerland Ag | Cząstki wirosomu zawierające antygeny wirusa grypy i wirusa zapalenia wątroby typu B |
US20070160628A1 (en) * | 2005-08-31 | 2007-07-12 | Birkett Ashley J | Stabilized virus-like particles and epitope display systems |
EP1764369A1 (de) * | 2005-09-16 | 2007-03-21 | Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH | Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants |
US8652782B2 (en) | 2006-09-12 | 2014-02-18 | Longhorn Vaccines & Diagnostics, Llc | Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids |
US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
US8084443B2 (en) | 2007-10-01 | 2011-12-27 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection and transport system and methods of use |
US8080645B2 (en) * | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
EP2185195A2 (en) * | 2007-08-16 | 2010-05-19 | Tripep Ab | Immunogen platform |
US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
CA2697373C (en) | 2007-08-27 | 2019-05-21 | Longhorn Vaccines & Diagnostics, Llc | Immunogenic compositions and methods |
US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
WO2010086743A2 (en) | 2009-02-02 | 2010-08-05 | Chrontech Pharma Ab | Compositions and methods that enhance an immune response |
SG178254A1 (en) | 2009-08-07 | 2012-03-29 | Transgene Sa | Composition for treating hbv infection |
PT2672992T (pt) | 2011-02-11 | 2020-07-27 | Univ Pennsylvania | Molécula de ácidos nucleicos codificando proteína nuclear do vírus da hepatite b e vacina compreendendo a mesma |
WO2013112916A1 (en) | 2012-01-26 | 2013-08-01 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
US10195267B2 (en) * | 2013-02-25 | 2019-02-05 | Klinikum Rechts Der Isar Der Technischen Universität München | Vaccination strategy |
CN105188710A (zh) | 2013-03-15 | 2015-12-23 | 葛兰素史密丝克莱恩生物有限公司 | 包含缓冲的氨基烷基氨基葡糖苷磷酸酯衍生物的组合物及其用于增强免疫应答的用途 |
WO2016183292A1 (en) | 2015-05-14 | 2016-11-17 | Longhorn Vaccines And Diagnostics, Llc | Rapid methods for the extraction of nucleic acids from biological samples |
CN107522777B (zh) * | 2017-09-13 | 2021-06-11 | 华兰生物疫苗股份有限公司 | 用于预防或治疗流感病毒的多肽、免疫原性偶联物及用途 |
CN107488217A (zh) * | 2017-09-13 | 2017-12-19 | 华兰生物疫苗有限公司 | 一种多肽、免疫原性偶联物和流感疫苗 |
CN111548395A (zh) * | 2020-05-25 | 2020-08-18 | 中国农业科学院兰州兽医研究所 | 一种口蹄疫病毒二价多表位重组病毒样颗粒及其应用 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4767842A (en) * | 1973-05-07 | 1988-08-30 | The Ohio State University | Antigenic modification of polypeptides |
US4977092A (en) * | 1985-06-26 | 1990-12-11 | Amgen | Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells |
US4643992A (en) * | 1982-11-09 | 1987-02-17 | Scripps Clinic And Research Foundation | Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives |
US4539205A (en) * | 1982-11-09 | 1985-09-03 | Scripps Clinic And Research Foundation | Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives |
US5093318A (en) * | 1983-11-01 | 1992-03-03 | Scripps Clinic And Research Foundation | Immunostimulating guanosine derivatives and their pharmaceutical compositions |
US5011828A (en) * | 1985-11-15 | 1991-04-30 | Michael Goodman | Immunostimulating guanine derivatives, compositions and methods |
US4818527A (en) * | 1986-12-09 | 1989-04-04 | Scripps Clinic And Research Foundation | T cell epitopes of the hepatitis B virus nucleocapsid protein |
US5143726A (en) * | 1986-12-09 | 1992-09-01 | The Scripps Research Institute | T cell epitopes of the hepatitis B virus nucleocapsid protein |
US4882145A (en) * | 1986-12-09 | 1989-11-21 | Scripps Clinic And Research Foundation | T cell epitopes of the hepatitis B virus nucleocapsid protein |
US4976958A (en) * | 1987-02-26 | 1990-12-11 | Scripps Clinic And Research Foundation | Mycobacterial recombinants and peptides |
US5057540A (en) * | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
JPH0198333A (ja) * | 1987-10-12 | 1989-04-17 | Nec Corp | 移動機所在地監視方式 |
EP0471056B1 (en) * | 1990-03-02 | 2001-10-17 | BP Corporation North America Inc. | Biosynthesis of carotenoids in genetically engineered hosts |
US5709879A (en) * | 1990-06-29 | 1998-01-20 | Chiron Corporation | Vaccine compositions containing liposomes |
EP0491077A1 (en) * | 1990-12-19 | 1992-06-24 | Medeva Holdings B.V. | A composition used as a therapeutic agent against chronic viral hepatic diseases |
ATE188613T1 (de) | 1992-06-25 | 2000-01-15 | Smithkline Beecham Biolog | Adjuvantien enthaltende impfstoffzusammensetzung |
HU219056B (hu) | 1993-03-23 | 2001-02-28 | Smithkline Beecham Biologicals Sa | 3-O-Dezacilezett monofoszforil-lipid A-t tartalmazó vakcinakészítmény |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
ATE420171T1 (de) * | 1994-07-15 | 2009-01-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US6113918A (en) * | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US6355257B1 (en) * | 1997-05-08 | 2002-03-12 | Corixa Corporation | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US7063967B2 (en) * | 1997-05-08 | 2006-06-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US6303347B1 (en) * | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
DK0996717T3 (da) | 1997-08-05 | 2006-04-10 | Vlaams Interuniv Inst Biotech | Immunbeskyttende influenzaantigen og anvendelse deraf til vaccination |
GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
US6024961A (en) * | 1997-11-14 | 2000-02-15 | Washington University | Recombinant avirulent immunogenic S typhi having rpos positive phenotype |
PT1042001E (pt) * | 1997-12-16 | 2002-09-30 | Chiron Corp | Uso de microparticulas combinadas com emulsoes submicronicas oleo-em-agua |
PL354714A1 (en) | 1998-04-09 | 2004-02-09 | Smithkline Beecham Biologicals S.A. | Adjuvant compositions |
US5990085A (en) * | 1998-05-04 | 1999-11-23 | Michigan State University | Inhibin-HBc fusion protein |
WO1999056776A2 (en) | 1998-05-07 | 1999-11-11 | Corixa Corporation | Adjuvant composition and methods for its use |
SE9903031D0 (sv) | 1999-08-27 | 1999-08-27 | Eurodiagnostica Ab | Peptide mixture and vaccine against a chronic viral infection |
EP1218514B1 (en) | 1999-10-08 | 2006-04-26 | Celltech Pharma Europe Limited | Designing immunogens |
CA2407897A1 (en) | 2000-05-05 | 2001-11-15 | Cytos Biotechnology Ag | Molecular antigen arrays and vaccines |
CA2413546C (en) | 2000-06-22 | 2011-06-14 | Celltech Pharmaceuticals Limited | Modification of hepatitis b core antigen |
US6942866B2 (en) * | 2000-08-16 | 2005-09-13 | Apovia, Inc. | Malaria immunogen and vaccine |
US20030138769A1 (en) | 2000-08-16 | 2003-07-24 | Birkett Ashley J. | Immunogenic HBc chimer particles having enhanced stability |
WO2003102165A2 (en) * | 2002-02-21 | 2003-12-11 | Apovia, Inc. | IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE |
US7361352B2 (en) | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
-
2003
- 2003-10-01 US US10/677,074 patent/US7351413B2/en not_active Expired - Fee Related
-
2004
- 2004-02-20 EP EP04713363A patent/EP1601327A4/en not_active Withdrawn
- 2004-02-20 CA CA 2516640 patent/CA2516640A1/en not_active Abandoned
- 2004-02-20 WO PCT/US2004/005047 patent/WO2004075836A2/en active Application Filing
- 2004-02-20 BR BRPI0407632-0A patent/BRPI0407632A/pt not_active IP Right Cessation
- 2004-02-20 MX MXPA05008677A patent/MXPA05008677A/es unknown
- 2004-02-20 NZ NZ541702A patent/NZ541702A/en unknown
- 2004-02-20 AU AU2004216246A patent/AU2004216246B2/en not_active Ceased
- 2004-02-20 KR KR1020057015418A patent/KR100815408B1/ko not_active IP Right Cessation
- 2004-02-20 CN CNA2004800105578A patent/CN101080239A/zh active Pending
- 2004-02-20 JP JP2006503739A patent/JP2007525421A/ja active Pending
-
2005
- 2005-09-20 ZA ZA200507617A patent/ZA200507617B/en unknown
Also Published As
Publication number | Publication date |
---|---|
NZ541702A (en) | 2008-08-29 |
WO2004075836A2 (en) | 2004-09-10 |
JP2007525421A (ja) | 2007-09-06 |
EP1601327A4 (en) | 2008-04-02 |
AU2004216246B2 (en) | 2008-08-07 |
KR20060028384A (ko) | 2006-03-29 |
WO2004075836A9 (en) | 2004-11-18 |
KR100815408B1 (ko) | 2008-03-20 |
WO2004075836A3 (en) | 2006-09-14 |
BRPI0407632A (pt) | 2006-02-21 |
CN101080239A (zh) | 2007-11-28 |
US7351413B2 (en) | 2008-04-01 |
AU2004216246A1 (en) | 2004-09-10 |
CA2516640A1 (en) | 2004-09-10 |
US20040156863A1 (en) | 2004-08-12 |
ZA200507617B (en) | 2007-02-28 |
EP1601327A2 (en) | 2005-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA05008677A (es) | Particulas quimericas de hbc estabilizadas como vacuna terapeutica para hepatitis cronica. | |
BR0113307A (pt) | Molécula de proteìna quimérica de núcleo de vìrus de hepatite b recombinante, partìcula imunogênica, vacina ou inóculo, ácido nucleico, molécula de ácido nucleico recombinante, célula hospedeira e método de induzir uma resposta imunológica em um animal hospedeiro inoculado | |
NO20063157L (no) | Influensa-immunogen og vaksine | |
EP1572234A4 (en) | STABILIZED PARTICLES OF HBC IMMUNOGENIC CHIMERS | |
AP2003002751A0 (en) | Malaria immunogen and vaccine | |
ATE320493T1 (de) | Modifizierung des hepatitis b kernantigens | |
CY1109257T1 (el) | Χιμαιρικες πρωτεϊνες l1 του ιου 16 ανθρωπινων θηλωματων που περιλαμβανουν l2 πεπτιδιο, ομοιαζοντα με ιο σωματιδια που παρασκευαζονται απο αυτες και μεθοδος παρασκευης των σωματιδιων | |
MXPA06001449A (es) | Antigenos quimericos para alterar la tolerancia del anfitrion a antigenos ajenos. | |
MXPA05005051A (es) | Vacuna de vector adenoviral. | |
WO2004048402A3 (en) | A hepatitis c virus codon optimized non-structural ns3/4a fusion gene | |
HK1081207A1 (en) | Hbv precore protein capable of forming particles | |
MY128999A (en) | Purification of hbv antigens for use in vaccines | |
WO2003102165A3 (en) | IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE | |
WO2003072731A3 (en) | STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS | |
TW201008576A (en) | New fusion proteins and their use for the preparation of vaccines against hepatitis C | |
JP2003514576A5 (es) | ||
ATE435660T1 (de) | Immunogenes polypeptid bestehend aus optimierten kryptischen peptiden aus tumorantigenen und seine verwendungen | |
WO2002088339A3 (fr) | Particules pseudovirales de birnavirus | |
JP2019506168A5 (es) | ||
WO2003072722A3 (en) | IMMUNOGENIC AVIAN HBc CHIMER PARTICLES HAVING ENHANCED STABILITY | |
EA200501330A1 (ru) | СТАБИЛИЗИРОВАННЫЕ ХИМЕРНЫЕ ЧАСТИЦЫ HBc В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОЙ ВАКЦИНЫ ПРОТИВ ХРОНИЧЕСКОГО ГЕПАТИТА | |
HK1067057A1 (en) | Angiotensin peptide-carrier conjugates and uses thereof | |
KR950700421A (ko) | 인위적 단백질분해 절단부위를 함유하는 재조합 비루스(Recombinant viruses comprising artificial proteolytic cleavage site) | |
LV14987B (lv) | Anti-HCV individuālas terapeitiskas vakcīnas prototips |